Coya Therapeutics, Inc.
COYA · XNASCIK 1835022fmd_0DWH0W4Q2QM4DVYVM2DAA1FJWAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Sep 30, 2026, 20 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | 0 | 6 | 4 | 8 |
| Research and development | 3 | 4 | 6 | 12 | 17 |
| Total operating expenses | 5 | 10 | 14 | 21 | 31 |
| Compensation and benefits | – | – | 3 | 3 | 3 |
| Operating income | (5) | (10) | (8) | (17) | (23) |
| Other non-operating income (expense) | (0) | 0 | 1 | 2 | 1 |
| Income before taxes | – | (12) | (7) | (16) | (21) |
| Income tax expense | – | 0 | 1 | (1) | 0 |
| Net income from continuing operations | – | (12) | (8) | (15) | (21) |
| Net income | (5) | (12) | (8) | (15) | (21) |